Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.
Iris G. Insogna, MD, MBE and Elizabeth S. Ginsburg, MD
Although the World Health Organization defines infertility as a disease, insurance coverage gaps generate disparities in access to care and treatment, especially for tubal factor infertility and oncofertility.
AMA J Ethics. 2018;20(12):E1152-1159. doi:
10.1001/amajethics.2018.1152.
Life extension requires careful consideration of resource scarcity, justice, and what, if anything, is intrinsic to the experiences we define as human.
AMA J Ethics. 2019;21(5):E470-474. doi:
10.1001/amajethics.2019.470.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?